However, several lines of evidence point to a more general association of MTSS1 and DNMT3B levels with survival: First, in additional analyses of the 183 AML patients described by Ley et al [34] and the Cancer genome Atlas Network (2013) and the 2096 patients described by Haferlach et al [35], high expression of MTSS1 was associated with the t(8;21) and inv(16) AML subsets while MTSS1 expression was low in 7q-deleted cases and t(11q23)-rearranged cases, both of which are associated with a poor prognosis (not shown). Here, DNMT3B is linked to acute myeloid leukemia.